Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Sees Large Increase in Short Interest

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 20,600 shares, an increase of 174.7% from the November 15th total of 7,500 shares. Based on an average trading volume of 44,000 shares, the days-to-cover ratio is currently 0.5 days.

Global X Genomics & Biotechnology ETF Stock Performance

Shares of Global X Genomics & Biotechnology ETF stock traded down $0.17 during midday trading on Friday, reaching $10.27. 164,994 shares of the company’s stock traded hands, compared to its average volume of 57,763. The company has a market cap of $75.07 million, a price-to-earnings ratio of -4.46 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a 52 week low of $9.52 and a 52 week high of $12.53. The company’s 50 day simple moving average is $10.61 and its 200 day simple moving average is $10.84.

Institutional Trading of Global X Genomics & Biotechnology ETF

Large investors have recently made changes to their positions in the stock. One Capital Management LLC raised its holdings in Global X Genomics & Biotechnology ETF by 22.1% in the 2nd quarter. One Capital Management LLC now owns 680,311 shares of the company’s stock worth $7,102,000 after acquiring an additional 123,339 shares during the period. Flow Traders U.S. LLC bought a new position in shares of Global X Genomics & Biotechnology ETF in the third quarter worth about $936,000. Oppenheimer Asset Management Inc. lifted its position in shares of Global X Genomics & Biotechnology ETF by 10.2% during the 2nd quarter. Oppenheimer Asset Management Inc. now owns 67,712 shares of the company’s stock worth $707,000 after purchasing an additional 6,260 shares during the last quarter. Corrado Advisors LLC boosted its stake in Global X Genomics & Biotechnology ETF by 3.0% during the 3rd quarter. Corrado Advisors LLC now owns 64,224 shares of the company’s stock valued at $723,000 after purchasing an additional 1,894 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Global X Genomics & Biotechnology ETF in the 2nd quarter valued at approximately $590,000. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.